Promising new therapies for treating previously untreatable cancers and other cellular hyperproliferative diseases have been discovered at the Dana Farber Cancer Institute (Boston, MA) and the Moffitt Cancer Center & Research Institute (Tampa, FL). GLG Pharma has the exclusive worldwide license to develop and market pharmaceutical products based on these discoveries. GLG Pharma is focusing the development of these compounds for the treatment of cancer and renal diseases.



These therapies are based on unique small molecules and formulations that inhibit dysfunctional STAT3 (Signal Transducer and Activators of Transcription) signaling. STAT3 is a signaling protein that is essential to cell growth. In normal cells, STAT3 signals are briefly turned on and off. In cancer cells, the signals are continuously activated; there is no off mechanism to stop cancer cells from multiplying out of control. This uncontrolled cell proliferation is also present in other diseases such as polycystic kidney disease.



The effectiveness of STAT3 inhibitors for some untreatable kidney disease e.g., polycystic kidney disease has been demonstrated in initial preclinical studies.



Thirty (30) different types of cancers have been shown to have dysfunctional STAT3 signaling. The effectiveness of STAT3 inhibitors in treating several of these cancers has been shown in clinical and preclinical studies.



STAT3 inhibitors can reverse resistance to 12 chemotherapeutic and targeted therapies in 9 different types of cancer. STAT3 inhibitors will be used to enhance/prolong the effectiveness of chemotherapy and other targeted therapies by preventing or treating acquired resistance to anticancer therapies.



A GLG Pharma drug for treating chronic lymphocytic leukemia is currently in Phase I/II clinical trials in combination with existing chemotherapies. Larger scale clinical trials are planned to begin in Poland in 2016.

STAT3 inhibitors combined with existing chemotherapies have shown promise in treating triple negative breast cancer.   Clinical trials are planned to begin in Poland in 2016.

STAT3 trials will also begin for untreatable polycystic kidney diseases.

GLG PHARMA has a unique diagnostic technology to first identify the patients that have abnormal STAT3 signaling and therefore would respond to our targeted treatments and second, to monitor biomarkers of abnormal STAT3 signaling and the effectiveness of treatments during clinical trials.

November 20, 2015 – Third Quarter Business Update Investor Conference Call for GLG Pharma

November 20, 2015 at 8:00AM ET / 2:00PM Central European time

Click Here